A phase II open-label trial to evaluate the efficacy and toxicity of Tarceva (erlotinib) in women with metastatic, hormone receptor negative and Her2-negative breast cancer
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2012 Actual end date (1 Apr 2011) added as reported by ClinicalTrials.gov.
- 02 Feb 2008 New trial record.